New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased cardiovascular risk, a daily orforglipron pill had cardiovascular safety comparable to daily insulin glargine injections while providing greater improvements in weight and blood sugar control. However, gastrointestinal (GI) adverse events were more common with orforglipron, leading to more treatment discontinuations. The study was sponsored by Eli Lilly, the manufacturer of orforglipron.
❓ Unknown
Daily Pill Offers Alternative to Insulin Injections for Diabetes Patients at Cardiovascular Risk
Oct 1, 2026
October 1, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
Recent research presented at the EASD meeting indicates that orforglipron, a daily pill for type 2 diabetes, may provide cardiovascular safety similar to insulin injections while improving weight and blood sugar control. This study, sponsored by Eli Lilly, highlights a potential shift in diabetes management that could impact healthcare approaches in Iran, particularly for patients at cardiovascular risk.
🔍 Quick Context Guide
💡 Bottom Line:
Orforglipron presents a promising alternative to insulin for diabetes management, with potential implications for patient care in Iran.
👥 Key Players
Eli Lilly
MENTIONED
Pharmaceutical company
"Eli Lilly is significant as they are the manufacturer of orforglipron, a potential alternative treatment for diabetes that could impact healthcare strategies in Iran."
European Association for the Study of Diabetes (EASD)
MENTIONED
Medical organization
"EASD is important for providing a platform for diabetes research, influencing treatment guidelines that may affect diabetes management in Iran."
📰 What Happened
Research presented at the EASD meeting indicates that orforglipron, a daily pill for type 2 diabetes, offers cardiovascular safety similar to insulin injections while improving weight and blood sugar control. However, it has higher rates of gastrointestinal side effects.
- Orforglipron may improve weight and blood sugar control compared to insulin glargine.
- Gastrointestinal side effects led to more treatment discontinuations with orforglipron.
💡 Why It Matters
🇮🇷 For Iran: This research could lead to changes in diabetes treatment protocols in Iran, potentially improving health outcomes for patients at cardiovascular risk.
🌍 Regional: If adopted, this treatment could influence diabetes management practices across the Middle East, where diabetes prevalence is high.
🌐 International: The findings may prompt further research and investment in diabetes treatments globally, affecting pharmaceutical markets.
📚 Background
Type 2 diabetes is a major health issue worldwide, often leading to cardiovascular complications. New treatments like orforglipron could change how the disease is managed.
Diabetes management
Cardiovascular health
📡 Source:
NEUTRAL
📊 Confidence:
70%
The information is derived from a reputable medical conference and publication, indicating a focus on scientific evidence.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
Just now •
Iran's Assembly of Experts Advocates for Reevaluation of Defense Doctrine and NPT Withdrawal
Just now •
Hassan Tehrani Moqaddam: A Visionary Who Transformed Iran into a Missile Power
Just now •